Here are three recent examples of corrupt corporate behavior. They show the breadth of the corruption – the leveraging of undeserved power and wealth – from corrupting government policy making to exacerbating economic inequality to corruptly maximizing profits.
U.S. Representative Richie Neal (Democrat of Massachusetts) received $54,000 in a two-month period from lobbyists for corporations with a financial stake in his actions that blocked meaningful control of health care costs. In December 2019, a bipartisan, House and Senate compromise on controlling health care costs was all set to pass as part of a larger appropriations bill. Among other things, the Lower Health Care Costs Act would have eliminated exorbitant surprise medical bills for out-of-network services by limiting their cost to that of equivalent in-network services. It also would have required pharmaceutical firms to disclose information related to increases in drug prices. 
Three days after the Lower Health Care Costs Act was finalized and on track to become law, Neal, Chairman of the powerful Ways and Means Committee, undermined it and got it dropped from the larger appropriations bill that was destined to pass into law. He did this by announcing that he and his Republican counterpart would draft a counterproposal, although no details were presented.
On February 7, 2020, less than two months later, Neal released his alternative bill. Key provisions of the Lower Health Care Costs Act had been eliminated or weakened. For example, rather than eliminating surprise medical bills, it included a weak substitute: voluntary negotiations and arbitration. The previous requirement for disclosures relevant to drug price increases was eliminated. In the two-month window from Neal’s blocking of the original bill to the release of his own much weaker bill, he collected $54,000 in donations from 12 lobbyists who worked for clients opposed to the original Lower Health Care Costs Act. These 12 donations represented two-thirds of his campaign contributions in the first quarter of 2020.
If this isn’t corruption, I don’t know what is. It appalls me that this is a legal and accepted campaign fundraising pattern. Clearly, we need to strengthen our campaign finance laws.
On a different front, a report from the Economic Policy Institute  found that in 2019 average pay was $21 million for Chief Executive Officers (CEOs) at the 350 largest corporations in the U.S. This is up 14% from the year before and 1,167% since 1978, while a typical worker’s pay has grown by only 14% since 1978. In other words, each $1.00 of a worker’s pay grew to $1.14 over those 40 years while each $1.00 of a CEO’s pay grew to $12.67. The ratio of CEO pay to the average worker’s pay is now 320 to 1, having grown dramatically from 61 to 1 in 1989 and 21 to 1 in 1965.
Skyrocketing CEO pay is a significant contributor to economic inequality, which continues to rise to unprecedented levels. The economy would not be harmed in the slightest if CEOs were paid less and/or taxed more.
There are many policy changes that would address excessive CEO pay if policy makers had the will to enact them, including:
- The income tax rate on high incomes could be increased to previous levels (which in the 1970s were roughly double current rates),
- Corporate tax rates could be increase for firms with high CEO-to-worker pay ratios, and
- A vote by shareholders could be required annually to approve CEO pay.
And then there’s the pharmaceutical industry that continually engages in corrupt corporate behavior, which displays its greed, market power, and lack of concern for stakeholders other than shareholders and executives. Two recent examples are summarized below.
First, Teva Pharmaceuticals is being sued by the federal government for illegally funneling $300 million through two charitable foundations to support the price and sales of its multiple-sclerosis drug, Copaxone. The Justice Departments suit claims the company used the foundations to insulate some patients from big price increases in order to prop up the excessive price of Copaxone for others. From 2007 to 2015, Copaxone’s price more than quadrupled from roughly $17,000 per year to over $73,000. 
In addition, in January 2020, Teva had paid a $54 million settlement for bribing doctors with fraudulent “speaking fees” to prescribe Copaxone and other drugs it makes.
Second, Gilead Sciences announced recently that it will charge patients with private insurance $3,120 for the five-day course of treatment with the experimental COVID-19 drug remdesivir. Some government programs may get a lower price and other developed countries will pay about 75% of the U.S. price. Reaction to the price has been mixed with some advocates and members of Congress saying Gilead is taking advantage of Americans during a pandemic. Taxpayers have invested about $100 million in the drug and some feel it should be public owned and not in private hands as a result. The U.S. Department of Health and Human Services (DHHS) recently purchased 500,000 treatment courses, three months’ worth of Gilead’s production, for an estimated $1.5 billion. DHHS will distribute the drug to hospitals around the country. 
Clearly, the U.S. needs stronger regulation of pharmaceutical firms, including disclosures relevant to drug pricing (like those in the Lower Health Care Cost Act). We also need to allow and empower Medicare and Medicaid to negotiate drug prices paid to pharmaceutical corporations, as the U.S. Veterans’ Administration, private insurers, and other countries do.
 Shaw, D., 5/5/20, “Neal took big bucks from lobbyists while killing a surprise medical bill fix,” Sludge (https://readsludge.com/2020/05/05/neal-took-big-bucks-from-lobbyists-while-killing-a-surprise-medical-bills-fix/)
 Mishel, L., & Kandra, J., 8/18/20, “CEO compensation surged 14% in 2019 to $21.3 million,” Economic Policy Institute (https://www.epi.org/publication/ceo-compensation-surged-14-in-2019-to-21-3-million-ceos-now-earn-320-times-as-much-as-a-typical-worker/)
 Bloomberg News, 8/19/20, “Talking points: Pharmaceuticals,” The Boston Globe
 Lupkin, S., 6/29/20, ”Remdesivir priced at more than $3,100 for a course of treatment,” National Public Radio (https://www.npr.org/sections/health-shots/2020/06/29/884648842/remdesivir-priced-at-more-than-3-100-for-a-course-of-treatment)